ME 102
Alternative Names: AutoVac™ prostrate cancer vaccine; AutoVac™ PSMA pharmaccine; AutoVac™ PSMA vaccine - Pharmexa; Prostate cancer vaccine - PharmexaLatest Information Update: 10 Jul 2007
At a glance
- Originator Pharmexa
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 22 Jun 2001 M&E Biotech is now called Pharmexa
- 27 Nov 1998 Preclinical development for Prostate cancer in Denmark (Unknown route)